Ranjana Advani
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma (NCT04788043) | Ranjana Advani | 2022-06-21 |
| Rituximab in Treating Patients With Hodgkin's Lymphoma (NCT00003820) | Ranjana Advani | 1999-01-01 |
Track Ranjana Advani automatically
Every clearance here is in the API, with alerts when new ones post.